Keyphrases
Operative
100%
Phase II Trial
100%
Transcriptional Response
100%
Celecoxib
100%
Primary Breast Cancer
100%
Antitumor
100%
Cyclooxygenase-2 Inhibitors
83%
Ki-67
50%
Placebo
33%
Quantitative PCR
33%
Cyclooxygenase-2
33%
Cleaved caspase-3
33%
Breast Cancer Tissues
33%
Extracellular Matrix
16%
Twice Daily
16%
Treatment Group
16%
Treatment Strategy
16%
Overexpression
16%
Breast Cancer Patients
16%
Gene Pathway
16%
Gene Expression
16%
Differentially Expressed Genes
16%
Path Analysis
16%
Underrepresentation
16%
Tumor Formation
16%
Antitumor Effect
16%
Transgenic
16%
Breast Cancer Cell Lines
16%
Expression Change
16%
Single Center
16%
Pre-surgical
16%
Antitumor Activity
16%
Phase II Study
16%
Surgical Excision
16%
Transcriptional Changes
16%
Associated Genes
16%
Fresh-frozen
16%
Protein Expression Analysis
16%
CD34
16%
Biological Response
16%
Angiogenesis Markers
16%
Proliferation Marker Ki-67
16%
Clinical Testing
16%
Control Arm
16%
Breast Cancer Model
16%
Neoangiogenesis
16%
Affymetrix
16%
Caspase-3 Expression
16%
Altered Pathway
16%
Transcriptional Program
16%
Inflammatory Immune Response
16%
Apoptosis Markers
16%
Surgical Biopsy
16%
Matrix Biology
16%
CD34 Expression
16%
Excision Specimen
16%
Downregulated Genes
16%
Immunology and Microbiology
Caspase
100%
Real-Time Polymerase Chain Reaction
100%
Cancer Tissue
100%
CD34
100%
Gene Expression
50%
Protein Expression
50%
Immune Response
50%
Extracellular Matrix
50%
Antineoplastic Activity
50%
Angiogenesis
50%
Expression Analysis
50%
Cell Cycle
50%
Arm
50%
Transgenics
50%
Breast Cancer Cell Line
50%
Medicine and Dentistry
Neoplasm
100%
Breast Cancer
100%
Phase II Trials
100%
Celecoxib
100%
Cyclooxygenase 2
75%
Placebo
25%
Real-Time Polymerase Chain Reaction
25%
Caspase 3
25%
Cancer Tissue
25%
Biopsy
12%
Group Therapy
12%
Gene Expression
12%
Carcinogenesis
12%
Protein Expression
12%
Programmed Cell Death
12%
Immune Response
12%
Antineoplastic Activity
12%
Angiogenesis
12%
Arm
12%
Cell Cycle
12%
Extracellular Matrix
12%
Expression Analysis
12%
Breast Cancer Cell Line
12%
Cyclooxygenase 2 Inhibitor
12%
Cancer Model
12%
Matrix (Biology)
12%
INIS
cancer
100%
tumors
100%
breasts
100%
genes
77%
inhibition
44%
potassium iodides
44%
patients
22%
surgery
22%
tissues
22%
pcr
22%
proliferation
22%
testing
11%
reduction
11%
biopsy
11%
matrices
11%
apoptosis
11%
inflammation
11%
proteins
11%
angiogenesis
11%
biology
11%
schedules
11%
arms control
11%
cell cycle
11%
proliferation (cell)
11%
Biochemistry, Genetics and Molecular Biology
Cyclooxygenase
100%
Celecoxib
100%
Phase II Trials
100%
Real-Time Polymerase Chain Reaction
33%
Caspase 3
33%
CD34
33%
Gene Expression
16%
Cancer Cell
16%
Protein Expression
16%
Carcinogenesis
16%
Immune Response
16%
Cell Cycle
16%
Transgenics
16%
Antineoplastic Activity
16%
Expression Analysis
16%
COX-2 Inhibitor
16%
Neoangiogenesis
16%